Search clinical trials for: CAR138 T Cells

Total 10907 results

Poseida Therapeutics, Inc.
Roche-Genentech

Recruiting

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)

Multiple Myeloma

United States
National Taiwan University Hospital

Not yet recruiting

CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies

Relapsed/Refractory B-Cell Malignancies
920th Hospital of Joint Logistics Support Force...

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Acute Myeloid Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

Cancers Which Are CD44v6 Positive

China
Poseida Therapeutics, Inc.

Active, not recruiting

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Metastatic Castration-resistant Prostate Cancer | Neoplasms... and other conditions

United States
Poseida Therapeutics, Inc.
California Institute for Regenerative Medicine (CIRM)

Terminated

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Multiple Myeloma

United States
Beijing Boren Hospital
Nanjing Legend Biotech Co.

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T-cell Leukemia | T Cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west...

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

China
Bellicum Pharmaceuticals

Active, not recruiting

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Hematologic Malignancy

Italy
Bellicum Pharmaceuticals

Active, not recruiting

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Anemia, Aplastic | Primary Immune Deficiency Disorder | Cytopenia | Osteopetrosis | Leukemia, Acute Myeloid (AML), Child | Hemoglobinopathy in Children

United States
Adaptimmune

Completed

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Melanoma | Head and Neck Cancer | Urothelial Carcinoma | Bladder Urothelial Carcinoma

United States, Canada, Spain
Peking Union Medical College Hospital

Unknown

A Study of EXP039 Treatment in Subjects With r/r NHL Subjects

Non-Hodgkin's B-cell Lymphoma

China
Fuda Cancer Hospital, Guangzhou
Jinan University Guangzhou

Completed

Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer

Pancreatic Cancer

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co., Ltd.

Unknown

Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.

CD123+ Acute Myeloid Leukemia

China
University College, London

Suspended

Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT (CMV_TCR-001)

CMV Infection | Haematological Malignancies

United Kingdom
Zhejiang University
Innovative Cellular Therapeutics Co., Ltd.

Unknown

CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

Lymphoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

Malignant Solid Tumors

China
Peking University
University of Florida

Unknown

Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas (4SCAR19273)

B-cell Lymphomas

China
Assistance Publique - Hôpitaux de Paris
Pierre and Marie Curie University; Université Paris XII

Completed

Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion (ILD-Treg)

Hematologic Neoplasms | Relapse

France
Xcyte Therapies

Completed

Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients

Chronic Lymphocytic Leukemia

United States
Celyad Oncology SA

Terminated

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer (LINK)

Colon Cancer Liver Metastasis

Belgium
Celyad Oncology SA

Unknown

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases (SHRINK)

Colon Cancer Liver Metastasis

Belgium
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Study of CT071 Injection in HRNDMM

High-risk Newly Diagnosed Multiple Myeloma (HRNDMM)
Ever Supreme Bio Technology Co., Ltd.

Not yet recruiting

A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors (CAR001)

Solid Tumor

Taiwan
RenJi Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

CAR-T Cell Therapy

China
Zhejiang University
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

CAR-T

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Autoimmune Diseases | Lupus Nephritis | Immune Nephritis

China
Precision BioSciences, Inc.

Recruiting

Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Hematologic Malignancy | CD19 Expressing Malignancies

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Sorrento Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma

United States
Xcyte Therapies

Unknown

T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

Multiple Myeloma

United States
Second Affiliated Hospital, School of Medicine,...
TCRx Therapeutics Co.Ltd

Not yet recruiting

TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy

Gastric Cancer | Gastroesophageal-junction Cancer
Fudan University
Guangzhou Bioresette Biomedical Technology Co., Ltd.; Chaosu Hu，Principal Investigator...

Recruiting

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Everett Meyer
National Cancer Institute (NCI)

Withdrawn

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

Graft Versus Host Disease

United States
AGC Biologics S.p.A.
Horizon 2020 - European Commission

Terminated

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Acute Myeloid Leukemia | Multiple Myeloma

Italy, Czechia
Radboud University Medical Center

Terminated

T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation

Lymphoma | Leukemia, Myeloid | Myelodysplastic Syndrome | Leukemia, Lymphocytic | Leukemia, Myeloid, Chronic

Netherlands
Baylor College of Medicine
National Cancer Institute (NCI); Stand Up To Cancer; Center for Cell and Gene... and other collaborators

Recruiting

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Sarcoma | Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Rhabdomyosarcoma | Synovial Sarcoma | HER-2 Protein Overexpression | Undifferentiated Sarcoma

United States
Children's National Research Institute

Recruiting

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

Solid Tumor

United States
Sheba Medical Center

Unknown

T-Cell Vaccination in Multiple Sclerosis (MS)

Multiple Sclerosis

Israel
Sheba Medical Center

Unknown

TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis

Multiple Sclerosis

Israel
UNC Lineberger Comprehensive Cancer Center
The Leukemia and Lymphoma Society; Bellicum Pharmaceuticals

Recruiting

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Immune System Diseases | Immunoproliferative Disorders | Acute Lymphoblastic Leukemia

United States
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals

No longer available

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

Immune System Diseases | Immunoproliferative Disorders | Acute Lymphoblastic Leukemia

United States
Shenzhen BinDeBio Ltd.
Henan Provincial People's Hospital

Recruiting

Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies

Glioma | Gastric Cancer | Hepatoma | Esophagus Cancer

China
Third Military Medical University

Unknown

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences

Terminated

T-cell Depleted Alternative Donor Transplantation

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Immune Deficiency | Lymphomas | Bone Marrow Failure | Osteopetrosis | Hemoglobinopathy

United States
Affiliated Hospital of Jiangnan University
West China Hospital; Hunan Cancer Hospital; Shenzhen Second People's Hospital; Zhejiang... and other collaborators

Recruiting

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Pleural Effusion, Malignant

China
Bioray Laboratories
First Affiliated Hospital of Zhejiang University

Recruiting

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China

Search clinical trials for: CAR138 T Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations